CClinicalTrials.gg
CompletedNCT06336811activeVRUpdated Mar 29, 2024

Virtual Reality Distraction During Phlebotomy in Children

An interventional study of passive virtual reality distraction and active virtual reality distraction in Pain, Acute, Child, Only and Anxiety and Fear, sponsored by Dokuz Eylul University. Completed at 1 site in Turkey. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-29.

Sponsored by Dokuz Eylul University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled May 2023, registered Mar 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

This randomized controlled study was conducted to evaluate the effect of distraction methods using virtual reality on the emotional appearance, pain, fear, and anxiety associated with the procedure during phlebotomy in children aged 6-12 in a private blood collection unit.

Read the detailed description

The data of the study was collected with Socio-demographic Data Collection Form, Emotional Appearance Scale for Children, Facial Expression Rating Scale, Child Anxiety Scale-State, and Child Fear Scale. Demographic data and mean scores obtained from the scales were compared between the virtual reality groups, and the control group.

02

Conditions studied

  • Pain, Acute
  • Child, Only
  • Anxiety and Fear

Browse trials for

Keywords

  • phlebotomy
  • virtual reality
03

In context

Acute Pain

876 studies on the registry are indexed under Acute Pain; 154 are open to participants now.

This study's enrollment of 150 is above the median of 90 across 732 interventional studies indexed under Acute Pain.

Browse Acute Pain studies →

Lead sponsor

Dokuz Eylul University is the lead sponsor of 252 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • The child agrees to participate in the study voluntarily.
  • The parent agrees to participate in the study voluntarily.
  • Obtaining consent forms from the child and parent

Exclusion criteria

Exclusion Criteria:

  • The child has a physical and psychological deficit that will prevent him from wearing the glasses that will be placed on his head to watch virtual reality.
  • Having fever (>37.5C) and severe dehydration
  • The patient did not take analgesics before the intervention
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
150 participants (actual)

Study arms

  • No intervention
    Control

    No additional intervention will be performed on the patient in the control group, and until the intervention begins, "How old are you?" Which grade are you in? What is the name of your favorite friend? Which sport do you enjoy doing more? His attention was distracted by asking questions such as.

  • Experimental
    active Virtual reality

    The remote control of the virtual glasses will be given to the hand that will not be interfered with, and the child will start, slow down or stop the application herself. Samsung Gear Oculus Guest 2 headset allows watching virtual reality applications.

    Device: active virtual reality distraction

  • Experimental
    passive virtual reality

    It was said that he could watch videos by wearing virtual headset glasses during the procedure. A virtual reality application that will attract the attention of children was determined by the researchers.

    Device: passive virtual reality distraction

Interventions

  • Devicepassive virtual reality distraction

    watching the application by wearing virtual glasses to the child during the phlebotomy

  • Deviceactive virtual reality distraction

    The remote control of the virtual glasses will be given to the hand, and the child will start, slow down or stop the application herself.

06

What researchers measure

Primary outcomes

  1. procedure related pain

    Wong-Baker FACES (WBS) Pain Rating Scale. This scale uses in children aged 3 and older to rate pain severity, ranges from 0 (very happy/no pain) to 10 (hurts worst).

    Time frame: 3 minutes after the phlebotomy

  2. anxiety

    The Children's Anxiety Meter (CAM-S). The Children's Anxiety Meter assesses children's anxiety and uses before medical procedures. This scale is drawn like a thermometer with a bulb at the bottom and also includes horizontal lines at intervals going up to the top (0-10). This scale ranges from 0 to 10. Higher values represent higher anxiety

    Time frame: 3 minutes before and after the phlebotomy

  3. fear

    The Child Fear Scale (CFS). The Child Fear Scale will use.This one-item scale measures procedure-related fear in children, consists of five sex-neutral faces, ranges from 0 (no fear) to extreme fear. This rating scale ranges from 0 to 4. It ranges from a no fear (neutral) face (0) on the far left to a face showing extreme fear on the far right. Higher scores mean a worse outcome. The rater responds indicates the level of fear.

    Time frame: 3 minutes before and after the phlebotomy

  4. emotional apperance

    This scale allows direct behavioral observation, consists of 5 different behavioral categories; 'Facial Expression', 'Speaking', 'Activity', 'Interaction' and 'Cooperation Level'. Scale scoring is done by reviewing the descriptions of behavior in each category and selecting the numerical value that most represents the observed behavior. Each category is scored from 1 to 5. The total score is made so that the numerical value is between 5-25 by adding the points obtained for each category. Higher scale score indicates the appearance of more negative emotional behaviors

    Time frame: 3 minutes before and after the phlebotomy

07

Study locations

1 site
  • Gülçin Özalp Gerçeker
    İzmir, 35100, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06336811
Lead sponsor
Dokuz Eylul University
Responsible party
Gülçin Özalp Gerçeker (Assoc. Prof., Dokuz Eylul University) — Principal investigator
First posted
Mar 29, 2024
Start date
May 30, 2023
Primary completion
Dec 30, 2023
Completion
Dec 30, 2023
Last update
Mar 29, 2024

Study contacts

Gulcin Ozalp
principal investigator · Dokuz Eylul University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion